Quantbot Technologies’s Agile Therapeutics AGRX Stock Holding History

Quantbot Technologies’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3	Closed	-$15K	–	1529
2019 Q4	$15K	Buy	+3	New	+$10.5K	﹤0.01%	1082

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantbot Technologies's AGRX Position: Q1 2020 in Review

Quantbot Technologies sold out of Agile Therapeutics (AGRX) in Q1 2020, closing a stake of 3 shares — an estimated $15K sold.

Quantbot Technologies first reported a position in AGRX in Q4 2019 and held it in 1 quarter. The position peaked at $15K in Q4 2019. 61 funds tracked by Wall St. Rank hold AGRX as of Q1 2020.

Quantbot Technologies reported no remaining Agile Therapeutics position as of Q1 2020 after selling out during the quarter.
Quantbot Technologies sold 3 Agile Therapeutics shares in Q1 2020, an estimated $15K.
Quantbot Technologies first reported a position in Agile Therapeutics in Q4 2019 and held it in 1 quarter.
Quantbot Technologies's Agile Therapeutics position peaked at $15K in Q4 2019.
61 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2020.

Based on Quantbot Technologies's 13F filing for Q1 2020, filed 13 May 2020.